Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-α formation with phosphodiesterase 4 (PDE4) selective inhibitors

Biochemical Pharmacology

Volumn 63, Issue 8, 2002, Pages 1527-1535

  Muise, Eric S ^a   Chute, Ian C ^a   Claveau, David ^a   Masson, Paul ^a   Boulet, Louise ^a   Tkalec, Lydia ^a   Pon, Douglas J ^a   Girard, Yves ^a   Frenette, Richard ^a   Mancini, Joseph A ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Asthma; Bronchoconstriction; Guinea pig; Phosphodiesterase 4; qPCR; TNF

Indexed keywords

4 [2 (3,4 BISDIFLUOROMETHOXYPHENYL) 2 (1,1,1,3,3,3, HEXAFLUORO 2 HYDROXYPROPAN 2 YL)PHENYLETHYL] 3 METHYLPYRIDINE 1 OXIDE; BIOLOGICAL MARKER; CYCLIC AMP; CYTOKINE; L 826141; LIPOPOLYSACCHARIDE; MESSENGER RNA; OVALBUMIN; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; BRONCHOSPASM; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; GUINEA PIG; HUMAN; IC 50; IN VITRO STUDY; KINETICS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; SPECIES DIFFERENCE; STIMULATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BRONCHOCONSTRICTION; DRUG INTERACTIONS; FEMALE; GUINEA PIGS; HUMANS; LIPOPOLYSACCHARIDES; MALE; OVALBUMIN; PHOSPHODIESTERASE INHIBITORS; POLYMERASE CHAIN REACTION; PYRIDINES; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037091049     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)00903-6     Document Type: Article

References (30)

1. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?
2. PDE isoenzymes as targets for anti-asthma drugs
3. The effects of anti-inflammatory and antiallergic drugs on the release of IL-1β and TNF-α in the human whole blood assay
4. Suppression of lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: Interaction with stimulants of adenylyl cyclase
5. The effects of anti-inflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A
6. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors
7. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst
8. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: Comparison with rolipram
9. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages
10. Differential regulation of human monocyte-derived TNF-α and IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors
11. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target
12. Cytokines, inflammation, and brain injury: Role of tumor necrosis factor-α
13. Immunomodulatory effect of tumor necrosis factor
14. Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance
15. Characterization of cAMP-dependent inhibition of LPS-induced TNF-α production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor
16. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages
17. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells
18. 2 and cyclic nucleotides
19. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells
20. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin-1 activity by increasing intracellular cyclic adenosine monophosphate
21. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
22. Interactive effects of the tumor necrosis factor promoter and 3′-untranslated regions
23. Regulation of the TNF-α gene
24. Relative contribution of transcription and translation to the induction of tumor necrosis factor-α by lipopolysaccharide
25. A canine model for determination of the therapeutic index of cytokine inhibitors
26. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation
27. 4 in a novel human whole blood assay
28. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks
29. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret
30. Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP